-
公开(公告)号：EP2904004B1
公开(公告)日：2018-11-21
申请号：EP13779684.3
申请日：2013-10-04
CPC分类号： C12N9/6467 , C07K14/001 , C07K14/4747 , C07K16/00 , C07K16/2863 , C07K16/30 , C07K2319/00 , C07K2319/01 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/33 , C07K2319/50 , C07K2319/55 , C12N9/6424
摘要： Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
-
2.发明公开BLYS FUSION PROTEINS FOR TARGETING BLYS RECEPTOR AND METHODS FOR TREATMENT OF B-CELL PROLIFERATIVE DISORDERS 审中-公开BLYS融合蛋白BLYS受体和方法的增生的B细胞干扰的靶向治疗
公开(公告)号：EP1855724A2
公开(公告)日：2007-11-21
申请号：EP06734163.6
申请日：2006-02-01
IPC分类号： A61K47/48 , C07K19/00 , C07K14/415 , C07K14/525 , A61P35/00
CPC分类号： C12N15/62 , A61K38/00 , A61K47/642 , C07K14/525 , C07K14/70575
摘要： The present invention regards targeted BLyS polypeptides capable of binding to BLyS receptors and that deliver a cytotoxic agent, such as a cytotoxic peptide, for example. In particular aspects, the cytotoxic agent comprises at least part of rGelonin. These compositions are useful for treating, preventing, and/or monitoring therapy for a B-cell proliferative disorder.
-
公开(公告)号：EP0743958B1
公开(公告)日：2003-07-23
申请号：EP95910893.7
申请日：1995-02-06
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6898 , A61K48/00 , C07K16/28 , C07K16/2863 , C07K16/32 , C07K2317/77 , C12N15/87
摘要： The present invention provides a non-viral vector, comprising a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. Also, provided is a method of introducing genetic material inside a specific cell comprising the administration of the non-viral vector to a human, wherein said non-viral vector comprises a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. In addition, there is provided a method of delivering a cytotoxic moiety to a cell comprising the administration of the non-viral vector to a human.
-
公开(公告)号：EP0743958A1
公开(公告)日：1996-11-27
申请号：EP95910893.0
申请日：1995-02-06
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6898 , A61K48/00 , C07K16/28 , C07K16/2863 , C07K16/32 , C07K2317/77 , C12N15/87
摘要： The present invention provides a non-viral vector, comprising a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. Also, provided is a method of introducing genetic material inside a specific cell comprising the administration of the non-viral vector to a human, wherein said non-viral vector comprises a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. In addition, there is provided a method of delivering a cytotoxic moiety to a cell comprising the administration of the non-viral vector to a human.
-
公开(公告)号：EP3456734A1
公开(公告)日：2019-03-20
申请号：EP18202465.3
申请日：2013-10-04
摘要： Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
-
公开(公告)号：EP2904004A2
公开(公告)日：2015-08-12
申请号：EP13779684.3
申请日：2013-10-04
CPC分类号： C12N9/6467 , C07K14/001 , C07K14/4747 , C07K16/00 , C07K16/2863 , C07K16/30 , C07K2319/00 , C07K2319/01 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/33 , C07K2319/50 , C07K2319/55 , C12N9/6424
摘要： Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
摘要翻译： 提供了细胞靶向的丝氨酸蛋白酶构建体。 这样的构建体可以用于靶向细胞杀伤的方法，例如增殖性疾病（例如癌症）的治疗细胞。 在一些方面，提供了显示改善的稳定性和细胞毒性的重组丝氨酸蛋白酶，例如粒酶B多肽。 还提供了用于治疗拉帕替尼或曲妥珠单抗抗性癌症的方法和组合物。
-
7.发明授权IMMUNOTOXINS DIRECTED AGAINST c-erbB-2 (HER-2/neu) RELATED SURFACE ANTIGENS 失效C-ERB B-2（HER-2 / NEU）VEWANDTE表面抗原免疫引导的
公开(公告)号：EP0635030B1
公开(公告)日：2004-07-21
申请号：EP93912147.1
申请日：1993-04-08
IPC分类号： C07K14/415 , A61K39/395 , A61K47/48
CPC分类号： A61K47/6825
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
